Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tenax Therapeutics (TENX) EPS (Basic) (2016 - 2026)

Tenax Therapeutics' EPS (Basic) history spans 8 years, with the latest figure at -$0.95 for Q4 2017.

  • On a quarterly basis, EPS (Basic) rose 96.91% to -$0.95 in Q4 2017 year-over-year; TTM through Dec 2017 was -$6.27, a 79.93% increase, with the full-year FY2025 number at -$1.34, down 16.52% from a year prior.
  • EPS (Basic) hit -$0.95 in Q4 2017 for Tenax Therapeutics, down from -$0.87 in the prior quarter.
  • Over the last five years, EPS (Basic) for TENX hit a ceiling of -$0.08 in Q3 2014 and a floor of -$30.73 in Q4 2016.
  • Historically, EPS (Basic) has averaged -$2.27 across 5 years, with a median of -$0.4 in 2014.
  • Biggest five-year swings in EPS (Basic): crashed 8436.11% in 2016 and later surged 96.91% in 2017.
  • Tracing TENX's EPS (Basic) over 5 years: stood at -$1.23 in 2013, then soared by 88.62% to -$0.14 in 2014, then tumbled by 157.14% to -$0.36 in 2015, then crashed by 8436.11% to -$30.73 in 2016, then surged by 96.91% to -$0.95 in 2017.
  • Business Quant data shows EPS (Basic) for TENX at -$0.95 in Q4 2017, -$0.87 in Q3 2017, and -$2.12 in Q2 2017.